top of page

Relevant reading: rheumatic irAEs

Key reviews on rheumatic irAEs

​

Rheumatic immune-related adverse events from cancer immunotherapy.

https://doi.org/10.1038/s41584-018-0074-9

​

Australian rheumatic irAE-relevant data

​

Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.

https://doi.org/10.1371/journal.pone.0192704

​

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.

https://doi.org/10.1016/j.ejca.2018.09.027

​

Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.

https://doi.org/10.1111/1756-185X.13444

​

Comments from Aus-REISAMIC members on rheumatic irAEs

​

Checkpoint inhibitors and arthritis.

https://doi.org/10.1136/annrheumdis-2018-213415

​

Letter to the editor: Comments on ‘A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica’.

https://doi.org/10.1016/j.ejca.2018.11.034

©2018 by Aus-REISAMIC.

bottom of page